RxDoctor Payments Data

Ricardo Adames, MD

Internal Medicine · Brownsville, TXNPI 1306806468

Payments from drug & device makers

$2,198in general payments, 2019–2025

Across 54 payments — averaging $40.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$543
  • AstraZeneca$303
  • Amarin Pharma, Inc.$255
  • Merck$229
  • Eisai Inc.$199
  • Inspire Medical Systems, Inc.$116
  • plus $553 from 9 others

What the payments were for

  • Food & beverage$2,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,198 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$70,221
Medicare patients
87
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin147$182,355
FarxigaDapagliflozin Propanediol129$129,400
OzempicSemaglutide132$127,232
JanuviaSitagliptin Phosphate74$97,748
TradjentaLinagliptin33$34,171
MyrbetriqMirabegron100$24,333
Tresiba Flextouch U-100Insulin Degludec31$21,967
EliquisApixaban31$21,286
TrulicityDulaglutide20$20,114
JanumetSitagliptin Phos/Metformin Hcl32$14,446
Levemir FlexpenInsulin Detemir29$10,386
Rosuvastatin Calcium342$7,489
NamzaricMemantine Hcl/Donepezil Hcl25$7,325
Icosapent Ethyl26$6,671
LevemirInsulin Detemir24$6,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$14$216,526180 claims
Novo NordiskOzempic, Levemir$543$133,521156 claims
AstraZenecaFarxiga$303$129,400129 claims
MerckJanuvia, Janumet$229$112,195106 claims
Lilly USA, LLCTrulicity$44$20,11420 claims
Sanofi-aventis U.S. LLCLantus$69$2,50222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →